EG-2201 (also known as NA-5F-PCZMO using EUDA systematic nomenclature) is a synthetic cannabinoid derived from a carbazole core group. It has been identified as a designer drug and is structurally related to other synthetic cannabinoids, such as EG-018 and MDMB-CHMCZCA. It is primarily used illicitly due to its psychoactive effects, which mimic delta-9-tetrahydrocannabinol (THC), the active ingredient in cannabis.
Chemical properties EG-2201 comprises a carbazole core group with a 5-fluoropentyl tail group, a methanone linker group, and a napthylenyl linked group. The use of a carbazole core group may increase CB2 receptor affinity compared to less bulky core groups like indoles and indazoles.
Pharmacology EG-2201 acts as an agonist of both human cannabinoid receptors, CB1 and CB2, at an affinity of 22.4 ± 12.8 nM and 4.36 ± 2.91 nM, respectively.
Risks and toxicity Limited toxicity studies exist for EG-2201, but related synthetic cannabinoids are associated with seizures, cardiovascular events, and psychiatric disturbances. Its metabolic byproducts may also be toxic.
See also Controlled substances
References